Generative AI-Based Data Analytics Solutions

BI MATRIX has signed a contract with Dong-A Pharmaceutical to implement its generative AI-based data analysis solution,
‘G-MATRIX.’

The standout feature of this project is integrating G-MATRIX with Microsoft’s collaboration tool, ‘Teams.’

Through this integration, users will be able to leverage G-MATRIX within the Teams app to quickly access data such as product and inventory information, even outside the office.

After the implementation, the sales department, which has a high demand for internal data usage, will be the first to adopt G-MATRIX.

The sales team, in particular, often needs to check inventory and sales data in real time while working externally. By directly accessing the corporate database via Teams, the accuracy and efficiency of their tasks are expected to be maximized.

Example screen from Teams / Source: BI MATIRX

Another key feature is that it boasts high accuracy with minimal training data.

G-MATRIX does not train on all the data a company holds; instead, it builds a “meta” and learns only specific information.

This approach means that rather than learning from the vast amount of corporate database data, the learning load is reduced, and the advantage is that the company’s database data is not exposed.

Additionally, since only the company’s database information is used, inaccurate and indiscriminate external data are not mixed in. By pre-training on the specific terms unique to the company and industry, it maintains high accuracy even when entering proprietary company data.

In this project, BI MATRIX will use its self-developed LLM, G-MATRIX MX-7B.

G-MATRIX MX-7B is an LLM specialized for corporate database data analysis. It has been lightweighted and optimized to fit corporate internal database analysis tasks, offering high processing performance while utilizing minimal hardware resources.

“With this order, BI MATRIX aims to accelerate the supply of G-MATRIX to the pharmaceutical industry. Following the adoption of generative AI solutions by Dong-A Pharmaceutical, one of Korea’s leading pharmaceutical companies, the demand for G-MATRIX implementation is expected to increase among other major domestic pharmaceutical companies.”
– BI MATIRX representative –

This project aims to expand its adoption across the entire company, starting